HopeStage
Back to all studies
CompletedNCT01376076

Heart-Rhythm Effects of Cariprazine in Schizophrenia

About this titleRead the official source — NCT01376076
Medication studyAges 18–50United States
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Listed locations
Glendale and 3 more locationsSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJune 2011
Recruitment status
Completed
Enrollment listed in the registry
129
Sponsor
Forest Laboratories
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 18 Years to 50 Years
Official registry ID
NCT01376076
Official title
Show the full official title

Evaluation of the Effects of Sequential Multiple-Dose Regimens of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Glendale · Long Beach · Willingboro

1 more locations
  • Houston

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Forest Laboratories, a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Cariprazine and Risperidone/Moxifloxacin.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies